Most Read Articles
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

Original New Drug Application Approvals by US FDA (16 - 31 March 2019)

02 Apr 2019
New drug applications approved by US FDA as of 16 - 31 March 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

ZYKADIA
  • Active Ingredient(s): Ceritinib
  • Strength:150 mg
  • Dosage Form(s) / Route(s): Tablet; Oral
  • Company: Novartis Pharms Corp
  • Approval Date: 18 Mar 2019
  • Submission Classification: Not Available
  • Indication(s): Indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
  • Approved Label: 18 Mar 2019 (PDF)

ZULRESSO
  • Active Ingredient(s): Brexanolone
  • Strength: 5 mg/mL
  • Dosage Form(s) / Route(s): Injectable; Injection
  • Company: Sage Therapeutics
  • Approval Date: 19 Mar 2019
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the treatment of postpartum depression (PPD) in adults.
  • Approved Label: 19 Mar 2019 (PDF)

MAYZENT
  • Active Ingredient(s): Siponimod
  • Strength: 0.25 mg; 2 mg
  • Dosage Form(s) / Route(s): Tablet; Oral
  • Company: Novartis Pharms Corp
  • Approval Date:  26 Mar 2019
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
  • Approved Label26 Mar 2019 (PDF)

JATENZO
  • Active Ingredient(s): Testosterone undecanoate
  • Strength: 237 mg
  • Dosage Form(s) / Route(s): Capsule; Oral
  • Company: Clarus Therapeutics Inc
  • Approval Date: 27 Mar 2019
  • Submission Classification: Type 3 - New Dosage Form
  • Indication(s): Indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
  • Approved Label27 Mar 2019 (PDF)

DUAKLIR PRESSAIR
  • Active Ingredient(s): Aclidinium bromide; formoterol fumarate dihydrate
  • Strength: 400 mcg / 12 mcg
  • Dosage Form(s) / Route(s): Powder; Inhalation
  • Company: AstraZeneca Pharms
  • Approval Date: 29 Mar 2019
  • Submission Classification: Type 4 - New Combination
  • Indication(s): Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)
  • Approved Label29 Mar 2019 (PDF)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 14 Oct 2019

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.